Team:MIT

From 2014.igem.org

(Difference between revisions)
Line 35: Line 35:
<table width=90% align=center>
<table width=90% align=center>
-
<tr><td><br><p style="font-size:15px" align=left><b>Alzheimer's disease is the sixth leading cause of death</b> in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association).  Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and existing diagnosis methods are unreliable.  <b>MIT iGEM 2014 is working to change this.</b>  We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a dynamic treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease.  Using the principles of synthetic biology, we designed a system that <b>detects molecular biomarkers</b> for Alzheimer's disease (neurotoxic beta-amyloid plaques and specific changes in miRNA levles) and <b>alters the levels of key enzymes</b> in response (BACE1 and BACE2, involved in beta-amyloid production and degradation, respectively). In the future, a system like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and alleviate the  
+
<tr><td><br><p style="font-size:15px" align=left><b>Alzheimer's disease is the sixth leading cause of death</b> in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association).  Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and, according to the clinicians that we interviewed, existing diagnosis methods are unreliable.  <b>MIT iGEM 2014 is working to change this.</b>  We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease.  Using the principles of synthetic biology, we designed a system that <b>detects molecular biomarkers</b> for Alzheimer's disease and <b>alters the levels of key enzymes</b> in response.  Our dynamic approach treats Alzheimer's disease only when its presence is detected, providing a specific, state-sensitive response. In the future, a system like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and improve the lives of their caretakers and family.
<tr><td><br><h3 style="font-size:35px" align=center><u>DETECTION  →  TREATMENT  →  DELIVERY</u></h3></td></tr>
<tr><td><br><h3 style="font-size:35px" align=center><u>DETECTION  →  TREATMENT  →  DELIVERY</u></h3></td></tr>

Revision as of 00:23, 17 October 2014

 


Image Map



Improving the Diagnosis and Treatment of

ALZHEIMER'S DISEASE


Neurodegenerative disease

Sixth leading cause of death in the US

Current diagnostics and therapeutics
are ineffective


Alzheimer's disease is the sixth leading cause of death in the United States, affecting more than 5 million Americans and resulting in the deaths of 500,000 people every year (Alzheimer's Association). Though one in three seniors dies with this disease (Alzheimer's Association), it currently has no cure, and, according to the clinicians that we interviewed, existing diagnosis methods are unreliable. MIT iGEM 2014 is working to change this. We set out to devise a way to diagnose Alzheimer's disease using biological rather than psychological tests and to invent a treatment mechanism that would capitalize on recent findings about the molecular pathology of the disease. Using the principles of synthetic biology, we designed a system that detects molecular biomarkers for Alzheimer's disease and alters the levels of key enzymes in response. Our dynamic approach treats Alzheimer's disease only when its presence is detected, providing a specific, state-sensitive response. In the future, a system like ours could provide a solution for patients suffering from the debilitating effects of Alzheimer's disease and improve the lives of their caretakers and family.


DETECTION → TREATMENT → DELIVERY


DETECTION


Native beta-amyloid receptor


Engineered B-cell receptor


miRNA sensors for Alzheimer’s state


TREATMENT

DELIVERY

Regulating beta-amyloid production
and degradation

Delivering our circuit